Trial of Endostar Combined With CHOPT for T Cell Lymphoma
To evaluate the efficacy and safety of Endostar combined with CHOPT in the treatment of T cell lymphoma.
T Cell Lymphoma
DRUG: Endostar and CHOPT
efficacy including overall response rate, progression free survival and overall survival, According to International Workshop Criteria, the number of participants with complete remission, partial remission and stable disease as a measure of efficacy.progressive free survival and overall survival of the participants are the second measure of efficacy, 1 year
safety of Endostar combined with CHOPT chemotherapy, Number of participants with adverse events as a measure of safety, 1 year
To evaluate the efficacy and safety of Endostar combined with CHOPT in the treatment of T cell lymphoma.